SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive data from GenFleet's GFH375 in KRAS-G12D mutant pancreatic cancer, showing promising ORR, DCR, and safety results compared to existing treatments. The community views this as a significant derisking event for VSTM's pipeline, potentially leading to blockbuster status and attracting institutional interest. Discussions also revolve around potential buyout scenarios and upcoming catalysts, amid volatility and short-selling pressures.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is gaining attention, particularly within the Phantom Wallet community on Solana, with many highlighting its potential for significant upside. Community members emphasize the coin's momentum and are encouraging others to buy in early, while some caution potential investors to be wary of a possible scam. The discussions suggest a focus on early adoption and potential gains within the Solana ecosystem.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending as investors discuss recent developments, including concerns about declining revenue guidance and the impact of a discount program. The community is also focused on the potential of their PHP platform and upcoming data from the CHOPIN trial. Some are speculating about a possible buyout or significant volatility ahead.

Atmos Energy Corp. engages in the provision of natural gas services. It operates through the Distribution and Pipeline and Storage segments. The Distribution segment is involved in regulated natural gas distribution and related sales operations. The Pipeline and Storage segment includes pipeline and storage operations of the Atmos Pipeline-Texas division and natural gas transmission operations. The company was founded in 1983 and is headquartered in Dallas, TX.

Atmos Energy Corp.

Atmos Energy ($ATO) is trending due to a mix of factors, including call option activity and recent analyst ratings. While some analysts have lowered price targets or downgraded the stock, others maintain a positive outlook, noting its defensive qualities amidst market volatility. Community discussion also highlights the stock's steady dividend and potential as a safe haven in uncertain economic times.

Analog Devices, Inc. is a semiconductor company, which engages in the combination of analog, digital, and software technologies into engineering solutions. Its products include analog and mixed signals, power management and reference, amplifiers radio frequency, and reference, sensors and actuators, and digital signal processing and system. The company was founded by Raymond P. Stata and Matthew Lorber in 1965 and is headquartered in Wilmington, MA.

Analog Devices Inc.

Analog Devices is trending due to a mix of analyst upgrades, positive reports on growth potential in the automotive and industrial sectors, and notable options activity. Community discussions highlight the company's strategic partnerships and its position to benefit from AI infrastructure buildout and advancements in 5G. Some investors are also looking at the company's dividend and potential for LEAPS.

Sprouts Farmers Market, Inc. engages in the operation of healthy grocery stores. The firm specializes in fresh, natural and organic products. Its products include fresh produce, bulk foods, vitamins and supplements, grocery, meat and seafood, deli, bakery, dairy, frozen foods, body care and natural household items. The company was founded by Stan Boney, Shon Alexander Boney, and Kevin K. Easler on July 11, 2002 and is headquartered in Phoenix, AZ.

Sprouts Farmers Market Inc

Sprouts Farmers Market is trending as the retail community debates its valuation amid upcoming earnings, with some suggesting it's overvalued while others point to strong fundamentals and growth potential. Community members are actively discussing technical patterns, potential price movements, and analysts' price targets. Some investors believe it's a safe haven during market uncertainty, while others express concerns about potential pullbacks and competition.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is sparking mixed reactions, with some community members pointing to whale accumulation and potential for utility, while others express concerns about the coin's long-term potential and the lack of recent pumps. Conversations also mention a "Shib on Solana" alternative. Traders are monitoring for potential buying opportunities amidst market volatility and the broader performance of meme coins.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as traders discuss its potential for a short squeeze and a breakout, with some anticipating a move towards the $40s. Community members are debating potential entry and exit points, while others express frustration with COMP's price action compared to other altcoins. Some investors are pointing to its low supply and potential for a significant upward move if volume increases.

Alchemy Pay

Alchemy Pay is trending as the community discusses its price action and potential. Recent partnerships and integrations, including one with Sony's Soneium, are being highlighted, though some traders express frustration with the token's inability to sustain gains. The upcoming launch of Alchemy Chain and its focus on stablecoin transactions is also generating buzz.

ViaSat, Inc. engages in providing communications technologies and services. It operates through the Communication Services and Defense and Advanced Technologies business segments. The Communication Services business segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets. The Defense and Advanced Technologies business segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging the company’s technical competencies in encryption, cyber security, tactical gateways, modems, and waveforms. The company was founded by Mark D. Dankberg and Mark J. Miller on May 1, 1986 and is headquartered in Carlsbad, CA.

Viasat, Inc.

Viasat is trending due to a prime contract award from the U.S. Space Force, igniting bullish sentiment. The community is focused on the company's growth phase, expansion plans, and potential breakout targets. Some are also discussing potential catalysts like future satellite launches and government contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Down 40% Year to Date: What Lies Ahead for the Stock? 

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects to advance a drug developed by Prothena into a late-stage study for ATTR amyloidosis with cardiomyopathy.On Stocktwits, retail sentiment around Prothena jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1332/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_1_09_34_PM_png_9facc97342.webp" alt="PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1332" height="122"><figcaption>PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for Prothena stock.<stembedurl>https://stocktwits.com/stocks271/message/623950128</stembedurl>Shares of Prothena traded 13% higher at the time of writing, while NYSE-listed shares of Novo traded 4% down.ATTR amyloidosis with cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease where misfolded transthyretin (TTR) proteins deposit in the heart muscle, leading to heart failure. Prothena-developed Coramitug is designed to deplete the abnormal protein deposits.Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. During Novo’s earnings call on Wednesday, the company said that it has successfully completed a mid-stage study of the drug and will now initiate a late-stage study during the course of 2025. The company also said that it will share detailed data from the mid-stage study at a medical conference later this year.Under the terms of the agreement between Prothena and Novo Nordisk, the former company is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones.Prothena is also eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the late-stage clinical trial. To date, Prothena has earned $100 million from the deal.PRTA stock is down by 43% this year and by about 61% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Equity

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.


Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well

RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.

AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? 

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD. 

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net cash burn from operating and investing activities to between $170 million and $178 million.&nbsp;The forecast follows a sweeping corporate restructuring that includes discontinuing development of birtamimab, an investigational therapy for AL amyloidosis, expected to reduce annual cash burn by about $96 million, and laying off 63% of its workforce.The biotech expects to end 2025 with roughly $298 million in cash, cash equivalents, and restricted cash at the midpoint.The revised cash burn outlook includes an estimated net loss of $240 million to $248 million, incorporating $36 million in non-cash share-based compensation and a $45 million non-cash tax expense related to deferred tax assets.The operating cost estimate includes $105 million to $110 million tied to birtamimab and reorganization-related expenses, such as severance and contract terminations.&nbsp;The company’s board and financial advisors are reviewing strategic options as it pivots to focus on its remaining pipeline and partnered programs.&nbsp;Prothena said it is reviewing strategic options as several clinical milestones approach, including Roche’s Phase 3 plans for prasinezumab in Parkinson’s, August data from Prothena’s PRX012 Alzheimer’s trial, and 2026 milestone payments of up to $105 million from partnered programs with Novo Nordisk and Bristol Myers Squibb.On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.One user expressed confidence in Prothena’s prospects, indicating the stock may have substantial upside potential and encouraging a broader, long-term perspective on its trajectory.<stembedurl>https://stocktwits.com/alromofi777/message/618389231</stembedurl>Another user said the cost and workforce reductions were largely anticipated, adding they plan to sell if shares hold above $6 on Friday following the recent rebound from lows.<stembedurl>https://stocktwits.com/SQUEAKSBANDIT/message/618364635</stembedurl>The stock has declined 57.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast

The biotech firm expects to end 2025 with nearly $300 million in cash as it pivots to focus on its Alzheimer’s and Parkinson’s pipeline.

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena Corporation plc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRTA News

PRTAProthena Corporation plc